Evidence map›Paper›PMID 41483096›Full record

ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2026

Telitacicept as a New Therapeutic Avenue for Generalized Myasthenia Gravis and Thymoma-Associated Myasthenia Gravis.

Ying Zhu, Benqiao Wang, Chunxiang Hu, Ruixia Zhu

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ying ZhuDepartment of Neurology, The First Affiliated Hospital of China Medical University, NO. 155 Nanjing Bei Street, Heping District, Shenyang, 110001, China.
Benqiao WangDepartment of Neurology, The First Affiliated Hospital of China Medical University, NO. 155 Nanjing Bei Street, Heping District, Shenyang, 110001, China.
Chunxiang HuDepartment of Neurology, The First Affiliated Hospital of China Medical University, NO. 155 Nanjing Bei Street, Heping District, Shenyang, 110001, China.
Ruixia ZhuDepartment of Neurology, The First Affiliated Hospital of China Medical University, NO. 155 Nanjing Bei Street, Heping District, Shenyang, 110001, China. zrx_200626313@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Generalized myasthenia gravis (gMG) is an antibody mediated autoimmune neuromuscular junction disorder characterized by muscle weakness and fatigue as well as acetylcholine receptor antibody (AChR-Ab) as the main presence. A proportion of patients fail to achieve minimal symptom expression (MSE), furthermore 10-20% of them develop into refractory under conventional immunotherapy. We conducted a retrospective study to explore the effectiveness and safety of telitacicept in gMG and thymoma-associated MG (TAMG) patients. The treatment response was assessed by the variation of QMG, MG-ADL and MG-QOL-15 scores. Time to MSE as well as usage of corticosteroid were also evaluated. In this retrospective study, we included 22 AChR-gMG patients (15 women, 7 men), including 7 refractory and 12 TAMG, who were treated with telitacicept by following-up at least 6 months. Compared to the baseline, a significant decrease in QMG, ADL and MG-QOL-15 scores was observed at every visit, especially for the QMG score with at least 3 points decline in all the patients in week 4. Twenty patients attained MSE and the time to MSE was 4 months during the observed period. At the last follow-up, the dose of prednisone of all the patients treated with telitacicept was ≤ 5 mg/d. The AChR-Ab titers and CD19

Indexed as

Myasthenia GravisThymomaThymus NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedRecombinant Fusion ProteinsRetrospective StudiesTreatment OutcomeYoung AdultRecombinant Fusion ProteinstelitaciceptAnti-acetylcholine receptor antibodyGeneralized myasthenia gravisRefractoryTelitaciceptThymoma-associated myasthenia gravis

Identifiers

PMID41483096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.